GO
Loading...

Merck & Co Inc

More

  • Stocks closed higher as investors overcame concerns about subprime lending to spark a late-day rally.  "We're going through a short-term bounce," Mark Arbeter, Chief Technical Strategist at Standard & Poor's, told CNBC.  "Volume, so far, on the upside has been fairly light, which is not encouraging. "

  • Vioxx Verdict Upheld; Merck Boosts CEO's Salary Tuesday, 6 Mar 2007 | 2:33 AM ET

    A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.

  • Answers To Your Questions About The Sell-Off Monday, 5 Mar 2007 | 9:15 PM ET

    Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....

  • Don't Believe the Hype Monday, 5 Mar 2007 | 6:14 PM ET

    It's time to step back from the madness and understand a basic tenet of the markets: Just because something negative happens somewhere, it doesn't mean the sky is falling. In fact, it could be good news for you. Here's why...

  • Good Pix Gone Bad Monday, 5 Mar 2007 | 6:01 PM ET

    On February 26th, Guy Adami, The Negotiator recommended this drug play. "Mylan Labs, you've gotta go the generic route… I'm going the generic route…I like Mylan Labs here. They had a nice earnings release I think this is a stock you have to own” Well guess what...

  • New Jersey Jury Splits on Two Merck Vioxx Cases Friday, 2 Mar 2007 | 4:35 PM ET

    A New Jersey jury found on Friday that Merck failed to provide adequate warnings about health risks tied to its withdrawn arthritis drug Vioxx in one case, but decided that it gave adequate warning in another in two suits tried simultaneously.

  • Cramer's Cure for a Market Hangover Wednesday, 28 Feb 2007 | 6:13 PM ET

    After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.

  • Stocks finished the day higher after the Fed chairman reassured investors that the economic outlook is not changed.  "The (markets) valuation, if anything, has gotten a little bit better," Goldman, Sachs chief U.S. investment strategist Abby Joseph Cohen said. "Going forward, what matters is that the global economy still looks good."

  • One in four U.S. women ages 14 to 59 is infected with the sexually transmitted virus that in some forms can cause cervical cancer, according to the first broad national estimate.

  • The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.

  • Stocks Close Lower on Economic Concerns, Higher Oil Monday, 26 Feb 2007 | 4:10 PM ET

    Stocks closed lower on concerns about economic growth and a rise in crude oil to its highest levels of the year. "Even with the corrective action we've seen since last week, consolidation is occurring in an orderly manner and that's positive," Gene Peroni, Senior Managing Director of Equity Research at Claymore Advisors, told CNBC.com.

  • Merck Stock Up After FDA Delays Novartis Diabetes Drug Monday, 26 Feb 2007 | 10:39 AM ET

    Merck's stock rose before the opening bell Monday after U.S. regulators asked for more data on rival Novartis' diabetes drug, which gives Merck a leg up in the race to launch a new class of diabetes drugs.

  • Drugmaker Merck said it would stop lobbying state legislatures to make it mandatory for schoolgirls to be inoculated with its new cervical cancer vaccine.

  • Merck plans to suspend its lobbying campaign to make its vaccination Gardasil mandatory, according to The Wall Street Journal's website.   Gardasil protects against the sexually transmitted virus that causes cervical cancer.

  • Big Pharma, Big Reforms Wednesday, 7 Feb 2007 | 1:11 PM ET

    Big Pharma is facing a dose of big reforms proposed by Congress. Some heavy-hitters are pushing for more oversight of the drug industry by strengthening the authority of the FDA. Do we need increased regulations and should the FDA be given more authority?  Those were the issues at the heart of a heated debate today on CNBC’s “Morning Call.”

  • Gardasil: On Guard Tuesday, 6 Feb 2007 | 10:54 AM ET

    The Governor of Texas announced on Friday that all girls entering the sixth grade in his state must get Merck's new vaccine, Gardasil, before they can enroll. Gardasil prevents four strains of the sexually-transmitted disease known as HPV which is the leading cause of cervical cancer. It works best when given before becoming sexually active. But the political and social backlash has already begun.

  • Ethical Debates Bog Down Merck's Vaccine Monday, 5 Feb 2007 | 2:59 PM ET

    Gov. Rick Perry of Texas recently ordered that all girls entering the sixth grade in that state be vaccinated against cervical cancer. The mandate has become a source of controversy from more than one angle. Does a governor have the right to make such an order? Is the vaccine safe? Could it promote sexual promiscuity? What role does Merck – the company that developed and produces the vaccine – play in all this?

  • Stocks Finish Higher Ahead of Fed; Energy Leads Gains Tuesday, 30 Jan 2007 | 6:56 PM ET

    A sharp rise in crude oil prices failed to deter investors on Tuesday as they nibbled at stocks ahead of the Federal Reserve's decision on interest rates, set for release tomorrow afternoon.

  • The company said fourth-quarter profit fell despite higher revenue as the drugmaker booked charges for restructuring, a large acquisition and increased legal reserves for painkiller Vioxx and osteoporosis drug Fosamax.

  • Fed On The Clock and Oil Firms Up Tuesday, 30 Jan 2007 | 7:46 AM ET

    The Dow is pointing higher this morning as investors focus on the Fed's two day meeting and a bunch of big earning reports. European markets are slightly weaker and Asian stocks were mixed overnight. The yen remains lower against the dollar.

Most Popular Video

Monday, 14 Apr 2014 | 11:43 AM ET

Dr. Steven Horng, Beth Israel Deaconess Medical Center, explains how Google Glass provided crucial support in an emergency situation and helped save a life.

Tuesday, 15 Apr 2014 | 11:36 PM ET

John Sculley, former Apple CEO and Managing Partner at Inflexionpoint, expects Alibaba to push on with its buying spree after listing in the U.S.

Thursday, 17 Apr 2014 | 4:00 PM ET

On this week's "$ave Me," CNBC's Kelli Grant gives tips on how to finally earn enough for that free airline award seat.